JP2004506420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004506420A5 JP2004506420A5 JP2002518256A JP2002518256A JP2004506420A5 JP 2004506420 A5 JP2004506420 A5 JP 2004506420A5 JP 2002518256 A JP2002518256 A JP 2002518256A JP 2002518256 A JP2002518256 A JP 2002518256A JP 2004506420 A5 JP2004506420 A5 JP 2004506420A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- nucleic acid
- probe
- antibody
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 101000994818 Agrotis ipsilon Insulin-related peptide 2 Proteins 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22286300P | 2000-08-04 | 2000-08-04 | |
| PCT/US2001/024747 WO2002012284A2 (en) | 2000-08-04 | 2001-08-06 | Iron regulating protein-2 (irp-2) as a diagnostic for neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004506420A JP2004506420A (ja) | 2004-03-04 |
| JP2004506420A5 true JP2004506420A5 (enExample) | 2009-03-05 |
Family
ID=22834032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002518256A Pending JP2004506420A (ja) | 2000-08-04 | 2001-08-06 | 神経変性疾患のための診断剤としての鉄調節タンパク質−２（ｉｒｐ−２） |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20020165349A1 (enExample) |
| EP (1) | EP1355933A2 (enExample) |
| JP (1) | JP2004506420A (enExample) |
| CN (1) | CN100535004C (enExample) |
| AU (1) | AU2001284742A1 (enExample) |
| CA (1) | CA2417310A1 (enExample) |
| MX (1) | MXPA03000937A (enExample) |
| RU (1) | RU2003105882A (enExample) |
| WO (1) | WO2002012284A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| ATE404877T1 (de) * | 2002-08-27 | 2008-08-15 | Kennedy Krieger Inst | Magnetische rezonanzbildgebung des mikrovaskulären blutvolumens |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| HRP20060073B1 (hr) | 2003-07-23 | 2014-03-14 | Bayer Healthcare Llc | Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja |
| CN101010315A (zh) * | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| JP4653542B2 (ja) * | 2005-04-06 | 2011-03-16 | 株式会社東芝 | 画像処理装置 |
| CN100448481C (zh) * | 2006-06-22 | 2009-01-07 | 中国科学院遗传与发育生物学研究所 | xCT蛋白及其编码基因的新用途 |
| WO2010068742A1 (en) * | 2008-12-12 | 2010-06-17 | Beckman Coulter, Inc. | Multicolor flow cytometry compositions containing unconjugated phycobiliproteins |
| US8580230B2 (en) * | 2009-02-23 | 2013-11-12 | Kent State University | Materials and methods for MRI contrast agents and drug delivery |
| EP2253716A1 (en) * | 2009-05-15 | 2010-11-24 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Diagnostic methods for the prognosis of a brain tumor |
| EP2642289A1 (en) | 2012-03-20 | 2013-09-25 | Sensirion AG | Portable electronic device |
| US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
| CN107636468A (zh) * | 2015-04-02 | 2018-01-26 | Crc心理健康有限公司 | 用于预测认知退化的风险的方法 |
| WO2018148788A1 (en) * | 2017-02-17 | 2018-08-23 | Crc For Mental Health Ltd | Method for predicting risk and rate of amyloid deposition and plaque formation |
| IT201700105483A1 (it) * | 2017-09-21 | 2019-03-21 | Braindtech S R L | Metodo per la diagnosi e la prognosi di patologie neurodegenerative e neuroinfiammatorie |
| JP6737995B2 (ja) * | 2018-11-29 | 2020-08-12 | 株式会社Ｒｅｓｖｏ | 精神疾患発症危険状態の診断用バイオマーカー |
| CN114446392B (zh) * | 2022-01-21 | 2024-01-30 | 华东理工大学 | 确认蛋白质与核酸适配体结合时的关键精氨基酸残基位点的方法 |
| CN114457067B (zh) * | 2022-02-10 | 2024-10-25 | 中国科学院天津工业生物技术研究所 | 一种低成本快速去除dna合成中错误的方法 |
| CN117417999B (zh) * | 2023-11-27 | 2025-07-25 | 河南省人民医院 | 一种与ireb2基因相关的snp分子标记及其应用 |
-
2001
- 2001-08-06 WO PCT/US2001/024747 patent/WO2002012284A2/en not_active Ceased
- 2001-08-06 RU RU2003105882/13A patent/RU2003105882A/ru unknown
- 2001-08-06 CN CNB018148549A patent/CN100535004C/zh not_active Expired - Fee Related
- 2001-08-06 EP EP01963822A patent/EP1355933A2/en not_active Withdrawn
- 2001-08-06 CA CA002417310A patent/CA2417310A1/en not_active Abandoned
- 2001-08-06 US US09/924,396 patent/US20020165349A1/en not_active Abandoned
- 2001-08-06 JP JP2002518256A patent/JP2004506420A/ja active Pending
- 2001-08-06 MX MXPA03000937A patent/MXPA03000937A/es unknown
- 2001-08-06 AU AU2001284742A patent/AU2001284742A1/en not_active Abandoned
-
2005
- 2005-07-01 US US11/174,166 patent/US20050260669A1/en not_active Abandoned
-
2007
- 2007-06-27 US US11/769,503 patent/US20080020393A1/en not_active Abandoned
-
2009
- 2009-10-21 US US12/603,411 patent/US20100041060A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004506420A5 (enExample) | ||
| RU2003105882A (ru) | Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях | |
| CN109765378B (zh) | 一种新的肝硬化或肝纤维化标志物 | |
| EP1325338A2 (en) | Diagnosis and treatment of alzheimer's disease | |
| US20040110938A1 (en) | Proteins, genes and their use for diagnosis and treatment of schizophrenia | |
| JP2004532386A (ja) | 多発性硬化症を診断および治療するためのタンパク質、遺伝子、およびこれらの使用 | |
| EP1384079A2 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| EP1408333A2 (en) | Diagnosis and treatment of Alzheimer's disease | |
| WO2001013117A2 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| US20030092614A1 (en) | ADPI-41, a novel protein isolated from brain tissue homogenate and uses therefor | |
| CN104450727A (zh) | X-连锁低磷酸盐血症性佝偻病的致病基因及其编码蛋白质和应用 | |
| CN105734070A (zh) | Corin基因变异体及其用途 | |
| JP2009506301A (ja) | Ｐｉｆファミリーの新たなタンパク質アイソフォーム及びその使用 | |
| JP2002518016A5 (enExample) | ||
| WO2001063293A2 (en) | Diagnosis and treatment of schizophrenia | |
| WO1999060122A1 (en) | Method for examining central nervous system diseases and method for screening remedies | |
| EP3928095B1 (en) | Use of bmmf1 rep protein as a biomarker for breast cancer | |
| JPH06503647A (ja) | ヒトホスホリパーゼ活性化タンパク質および慢性関節リウマチの診断の方法 | |
| CA2461199A1 (en) | Atlastin | |
| EP1264183A2 (en) | Diagnosis and treatment of vascular dementia | |
| CN1341753A (zh) | 利用牙本质唾磷蛋白基因及其编码产物诊断和治疗牙本质生成不全ⅱ型的方法 | |
| JP2005124565A (ja) | 新規神経ペプチド及びその利用 | |
| EP1313875A2 (en) | Method of diagnosing, monitoring, staging, imaging and treating colon cancer | |
| JP3616274B2 (ja) | 中枢神経系疾患の検査方法および治療薬のスクリーニング方法 | |
| JP2006516888A5 (enExample) |